Compare AU
Compare VNGS vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vaughan Nelson Global Smid Fund (Managed Fund) (VNGS) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VNGS | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 83 |
Median incremental investment | $0 | $619.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,437.24 |
Average age group | N/A | > 35 |
Key Summary
VNGS | CURE | |
|---|---|---|
Strategy | VNGS.AX was created on 2022-06-01 by Vaughan. The fund's investment portfolio concentrates primarily on extended market equity. The Fund aims to outperform the MSCI ACWI SMID Cap Index (after fees and expenses and before taxes) on a rolling five-year basis. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Monolithic Power Systems Inc (3.37 %) Element Solutions Inc (3.09 %) Cushman & Wakefield PLC (2.66 %) | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) |
Top 3 industries | Other (21.22 %) Information Technology (19.22 %) Financials (15.49 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (58.61 %) United Kingdom of Great Britain and Northern Ireland (11.67 %) Japan (4.24 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 1.12 % | 0.45 % |
Key Summary
VNGS | CURE | |
|---|---|---|
Issuer | Vaughan | Global X |
Tracking index | MSCI ACWI SMID Cap Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 1.12 % | 0.45 % |
Price | $3.29 | $51.33 |
Size | $27.627 million | $36.301 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | - % | 4.24 % |
Market | ASX | ASX |
First listed date | 31/05/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VNGS | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 83 |
Median incremental investment | $0 | $619.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,437.24 |
Average age group | N/A | > 35 |
Pros and Cons
VNGS | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VNGS | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |